Baricitinib for the treatment of rheumatoid arthritis.

Abstract:

INTRODUCTION:Rheumatoid arthritis (RA) is characterized by systemic synovitis causing joint destruction. With the development of biological disease-modifying anti-rheumatic drugs (bDMARDs) and combination of conventional DMARDs, clinical remission is perceived as an appropriate and realistic goal in many patients. However, bDMARDs require intravenous or subcutaneous injection and some patients fail to respond to bDMARDs or lose their primary response. Under the circumstances, targeted synthetic DMARDs (tsDMARDs), which are orally available low-molecular weight products, have been emerging. Five phase 3 trials of Baricitinib, a JAK1 and JAK2 inhibitor, have been performed and showed high clinical efficacy in patients with active RA and naïve to sDMARDs or an inadequate response to sDMARDs, MTX or bDMARDs. There was a favorable response for clinical and functional parameters in studies with placebo, MTX and adalimumab as comparator. It is also reported that safety was tolerable within the limited study period. AREAS COVERED:We here review the recent progress in the development of baricitinib and its potential for the treatment of RA. Expert commentary: Although baricitinib is only one of the highly effective DMARDs that has a new mode of action, it will bring new concepts for rheumatology in the future.

authors

Kubo S,Nakayamada S,Tanaka Y

doi

10.1080/1744666X.2016.1214576

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

911-9

issue

9

eissn

1744-666X

issn

1744-8409

journal_volume

12

pub_type

杂志文章,评审
  • Concurrent use of antioxidants in cancer therapy: an update.

    abstract::Some chemotherapeutic agents and all radiation therapy generates reactive oxygen species (ROS), which induce apoptosis in cancer cells. As ROS play a role in drug-induced apoptosis, one might suspect that antioxidants may inhibit ROS and prevent apoptosis of cancer cells. In order to find an answer to whether or not t...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.6.931

    authors: Akbas HS,Timur M,Ozben T

    更新日期:2006-11-01 00:00:00

  • Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.

    abstract::The 12/15-lipoxygenase (LO) cascade governs the generation of 12-hydroperoxy-eicosatetraenoic acid (HPETE) and 15-HPETE from arachidonic acid. The 5-LO pathway plays a fundamental role in the biosynthesis of leukotrienes, essential inflammatory lipid mediators. Cyclooxygenase (COX)-1 and -2 biosynthetic pathways are r...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2.4.649

    authors: Zhao L,Grosser T,Fries S,Kadakia L,Wang H,Zhao J,Falotico R

    更新日期:2006-07-01 00:00:00

  • Hematopoietic stem cell transplantation in multiple sclerosis: a review of the clinical experience and a report of an international meeting.

    abstract::Hematopoietic stem cell transplantation (HSCT), both allogeneic and autologous, has become one of the hottest topics in clinical immunology. One of the main autoimmune diseases in which HSCT has been extensively tried during the last decade is multiple sclerosis (MS). A few original papers and many anecdotal reports h...

    journal_title:Expert review of clinical immunology

    pub_type:

    doi:10.1586/eci.10.7

    authors: Karussis D,Vaknin-Dembinsky A

    更新日期:2010-05-01 00:00:00

  • Potential and limitations of regulatory T-cell therapy in solid organ transplantation.

    abstract::Over the past few years, the therapeutic potential of Treg has been highlighted in the field of autoimmune diseases and after allogeneic transplantation. The first hurdle for the therapeutic use of Treg is their insufficient numbers in non-manipulated individuals, in particular when facing strong immune activation and...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2014.943191

    authors: Govender L,Pascual M,Golshayan D

    更新日期:2014-09-01 00:00:00

  • Discontinuation of immunoglobulin replacement therapy in patients with secondary antibody deficiency.

    abstract:INTRODUCTION:Secondary immunodeficiency is becoming a greater medical concern as the usage of immunosuppressive and biological treatments has increased. Individuals with certain medical conditions, such as hematological malignancies, can also have secondary immunodeficiency. Immunoglobulin replacement therapy (IGRT), w...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1080/1744666X.2020.1788939

    authors: Patel V,Cowan J

    更新日期:2020-07-01 00:00:00

  • Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.

    abstract::Ulcerative colitis is a chronic condition that requires long-term treatment. The first-line therapy remains 5-aminosalicylic acid, which is available in several different formulations and dosing schedules. Several studies have demonstrated that adherence rates to prescribed 5-aminosalicylic acid products are below tho...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.10.28

    authors: Bernick SJ,Kane S

    更新日期:2010-07-01 00:00:00

  • Transplantation in highly sensitized patients: challenges and recommendations.

    abstract:INTRODUCTION:Highly sensitized patients awaiting a kidney transplant accrue on the transplant waiting list. The breadth of HLA antibodies in this subpopulation of patients precludes receiving a compatible organ offer through regular allocation within an acceptable time-frame. Areas covered: Several alternative options ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1498335

    authors: Heidt S,Claas FHJ

    更新日期:2018-08-01 00:00:00

  • Cohort of Iranian Patients with Congenital Agammaglobulinemia: Mutation Analysis and Novel Gene Defects.

    abstract:OBJECTIVES:Impairment in early B-cell development can cause a predominantly antibody deficiency with severe depletion of peripheral B-cells. Mutations in the gene encoding for Bruton's-tyrosine-kinase (BTK) and the components of the pre-B-cell receptor complex or downstream signaling molecules have been related to this...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.2016.1139451

    authors: Abolhassani H,Vitali M,Lougaris V,Giliani S,Parvaneh N,Parvaneh L,Mirminachi B,Cheraghi T,Khazaei H,Mahdaviani SA,Kiaei F,Tavakolinia N,Mohammadi J,Negahdari B,Rezaei N,Hammarstrom L,Plebani A,Aghamohammadi A

    更新日期:2016-01-01 00:00:00

  • Novel therapies for the antiphospholipid syndrome.

    abstract::Antiphospholipid antibodies (aPL Abs) are associated with thrombosis in patients with the antiphospholipid syndrome (APS). There is strong evidence that aPL Abs are pathogenic in vivo from studies in animal models. Furthermore, there are now convincing data indicating that activation of complement is involved in those...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.2.193

    authors: Pierangeli SS

    更新日期:2008-03-01 00:00:00

  • Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies.

    abstract:BACKGROUND:Biological drugs, mainly interleukin (IL)-1 and IL-6 antagonists, but also tumor necrosis factor (TNF) inhibitors, have been used in the treatment of adult onset Still's disease patients (AOSD). METHODS:We summarised the available evidence for the effectiveness of biologic drugs in AOSD. A systematic review...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/1744666X.2017.1375853

    authors: Ruscitti P,Ursini F,Cipriani P,De Sarro G,Giacomelli R

    更新日期:2017-11-01 00:00:00

  • Dietary therapies for eosinophilic esophagitis.

    abstract::Eosinophilic esophagitis (EoE) represents a prevalent chronic esophageal disorder. Since the condition was first described, its pathophysiology has been known to have an immune-allergic origin, but the high response rate to dietary therapies based on feeding patients exclusively with amino acid-based elemental formula...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.856263

    authors: Arias A,Lucendo AJ

    更新日期:2014-01-01 00:00:00

  • Rescue therapy: ciclosporin or infliximab?

    abstract::Severe active refractory ulcerative colitis is a potentially life-threatening disease. The introduction of intensive steroid treatment and early surgery has reduced mortality in recent years. Ciclosporin and infliximab are effective rescue therapies in steroid refractory colitis. A head-to-head study proposed by Lahar...

    journal_title:Expert review of clinical immunology

    pub_type: 评论,杂志文章

    doi:10.1586/eci.13.34

    authors: Rizzello F,Praticò C,Calabrese C,Gionchetti P

    更新日期:2013-06-01 00:00:00

  • Psoriatic arthritis: lessons from imaging studies and implications for therapy.

    abstract:INTRODUCTION:Modern imaging may aid in the diagnosis, prognosis and monitoring of therapeutic response in psoriatic arthritis (PsA). Detection of osteitis and technical advances like whole body magnetic resonance imaging (MRI) exemplify the value of this technology. Areas covered: Ultrasound (US) provides a clinic-base...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1215245

    authors: Mathew AJ,Coates LC,Danda D,Conaghan PG

    更新日期:2017-02-01 00:00:00

  • New insights into the pathogenesis of giant cell arteritis and hopes for the clinic.

    abstract::Giant cell arteritis is a complex immune-mediated disease that involves large blood vessels in individuals older than 50 years. Recent studies have confirmed a strong association of this form of vasculitis with the HLA region, particularly with HLA class II genes. However, other non-HLA loci, such as protein tyrosine ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2016.1089173

    authors: Carmona FD,Martín J,González-Gay MA

    更新日期:2016-01-01 00:00:00

  • New biologics for allergic diseases.

    abstract:INTRODUCTION:Allergic conditions such as asthma and atopic dermatitis have a high prevalence but represent a heterogeneous group of diseases despite similar clinical presentation and underlying pathophysiology. A better understanding of the phenotypes and endotypes of these diseases has driven rapid development of biol...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1459188

    authors: Manka LA,Wechsler ME

    更新日期:2018-04-01 00:00:00

  • Adalimumab for the treatment of uveitis.

    abstract:INTRODUCTION:Adalimumab, an inhibitor of tumor necrosis factor-alpha (TNFα), is the only systemic non-corticosteroid agent which has been approved by the US Food and Drug Administration (FDA) for the treatment of non-infectious uveitis. Areas covered: The aim of this review is to summarize the research which demonstrat...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2017.1288097

    authors: LaMattina KC,Goldstein DA

    更新日期:2017-03-01 00:00:00

  • Adalimumab for the treatment of psoriatic arthritis.

    abstract::Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring in 6-39% of patients with psoriasis. Standard therapy of PsA includes nonsteroidal anti-inflammatory drugs, intra-articular steroids and disease-modifying antirheumatic drugs. Failure of standard therapy is an indication for anti-TNF-alpha the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.50

    authors: Poddubnyy DA,Rudwaleit M

    更新日期:2009-11-01 00:00:00

  • Prediction of treatment outcome and relapse in inflammatory bowel disease.

    abstract:INTRODUCTION:Prediction of treatment outcome and clinical relapse in patients with inflammatory bowel disease (IBD), either ulcerative colitis (UC) or Crohn's disease (CD), is particularly important because therapeutics for IBD are not always effective and patients in remission could frequently relapse. Because undergo...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1593140

    authors: Kato J,Yoshida T,Hiraoka S

    更新日期:2019-06-01 00:00:00

  • Dendritic cell-based therapy in Type 1 diabetes mellitus.

    abstract::Dendritic cell (DC) immunotherapy is a clinical reality. Despite two decades of considerable data demonstrating the feasibility of using DCs to prolong transplant allograft survival and to prevent autoimmunity, only now are these cells entering clinical trials in humans. Type 1 diabetes is the first autoimmune disorde...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.09.8

    authors: Phillips B,Giannoukakis N,Trucco M

    更新日期:2009-05-01 00:00:00

  • Nutrigenetics, nutrigenomics and inflammatory bowel diseases.

    abstract::Inflammatory bowel disease includes ulcerative colitis and Crohn's disease, which are both inflammatory disorders of the gastrointestinal tract. Both types of inflammatory bowel disease have a complex etiology, resulting from a genetically determined susceptibility interacting with environmental factors, including the...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2013.824245

    authors: Ferguson LR

    更新日期:2013-08-01 00:00:00

  • Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility.

    abstract::Epidemiological and clinical studies have suggested that the pathogenesis of inflammatory bowel disease (IBD) is strongly influenced by genetic predisposition. Beyond the limitations of linkage analysis, multiple genome-wide association studies, their meta-analyses, and targeted genotyping array techniques have broade...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2016.1184972

    authors: Ye BD,McGovern DP

    更新日期:2016-10-01 00:00:00

  • New frontiers in reproductive immunology research: bringing bedside problems to the bench.

    abstract::The 31st Annual Meeting of the American Society for Reproductive Immunology provided an excellent platform for basic and clinical scientists to brainstorm on current reproductive health issues such as repeated implantation and pregnancy failure, preterm birth, preeclampsia and genital tract infections such as HIV. The...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/eci.11.47

    authors: Joukhadar J,Nevers T,Kalkunte S

    更新日期:2011-09-01 00:00:00

  • Chronotherapy with modified-release prednisone in patients with rheumatoid arthritis.

    abstract::Glucocorticoids are indispensable for the treatment of systemic inflammatory diseases such as rheumatoid arthritis (RA), though their beneficial effects have to be balanced with potential complications arising from high doses, prolonged use or dose splitting. A glucocorticoid formulation (modified-release prednisone) ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/eci.11.95

    authors: Alten R

    更新日期:2012-02-01 00:00:00

  • Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares.

    abstract::Evaluation of: Tseng CE, Buyon JP, Kim M et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54, 3623-36...

    journal_title:Expert review of clinical immunology

    pub_type: 评论,杂志文章

    doi:10.1586/1744666X.3.3.267

    authors: Cardiel MH,Almagro RM

    更新日期:2007-05-01 00:00:00

  • Cancer immunomics and application of 'omics' for cancer management.

    abstract::Several 'omics' sciences have been launched. The outstanding diversity of immune system components, together with the complexity of the regulatory pathways and network-type interactions, makes immunology a combinatorial science. Cancer immonomics is a branch of immunomics. The present cancer immunomics project aims at...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.3.5.807

    authors: Wiwanitkit V

    更新日期:2007-09-01 00:00:00

  • Perspectives on complementary and alternative therapies in asthma.

    abstract::Asthma is a chronic disease that affects millions of individuals living in the USA. Proper asthma management is essential for controlling asthma symptoms and exacerbations. In recent years, however, there has been increased recognition of individuals using complementary and alternative medicine (CAM) to treat asthma. ...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章

    doi:10.1586/1744666X.4.6.703

    authors: Adams SK,Koinis-Mitchell D

    更新日期:2008-11-01 00:00:00

  • New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.

    abstract:INTRODUCTION:Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there are differences related to the different mechanisms of action. Areas covered: We review the m...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2018.1454835

    authors: Carrascosa JM,Del-Alcazar E

    更新日期:2018-04-01 00:00:00

  • Omalizumab for the treatment of chronic urticaria.

    abstract::Urticaria is a common and often debilitating dermatological condition defined by the sudden appearance of wheals, angioedema or both. It is further classified into specific subtypes based on duration and specific triggers. Awareness and understanding of urticaria are important to ensure a correct initial diagnosis and...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2015.993971

    authors: Zuberbier T,Maurer M

    更新日期:2015-02-01 00:00:00

  • Regulatory T cells: the future of autoimmune disease treatment.

    abstract::Introduction: CD4 + T regulatory cells (Tregs) have been described as the most potent immunosuppressive cells in the human body. They have been found to control autoimmunity, and clinical attempts have been made to apply them to treat autoimmune diseases. Some specific pathways utilized by Tregs in the regulation of i...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1080/1744666X.2019.1620602

    authors: Ryba-Stanisławowska M,Sakowska J,Zieliński M,Ławrynowicz U,Trzonkowski P

    更新日期:2019-07-01 00:00:00

  • Tests for evaluating non-immediate allergic drug reactions.

    abstract::Non-immediate drug reactions (NIR) are induced by specific immunological mechanisms and involve the recognition of hapten molecules by the immune system, with the participation of dendritic cells and other antigen-presenting cells. This process is followed by an effector response that can induce several clinical entit...

    journal_title:Expert review of clinical immunology

    pub_type: 杂志文章,评审

    doi:10.1586/1744666X.2014.966691

    authors: Perkins JR,Ariza A,Blanca M,Fernández TD

    更新日期:2014-11-01 00:00:00